2020

Connock, Martin, Andronis, Lazaros, Auguste, Peter, Dussart, Claude and Armoiry, Xavier (2020) Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opinion on Biological Therapy, 20 (7). pp. 823-827. doi:10.1080/14712598.2020.1772747

2019

Gallacher, Daniel C., Auguste, Peter, Royle, Pamela, Mistry, Hema and Armoiry, Xavier (2019) A systematic review of economic evaluations assessing the cost-effectiveness of licensed drugs used for previously treated epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced/metastatic non-small cell lung cancer. Clinical Drug Investigation, 39 . pp. 1153-1174. doi:10.1007/s40261-019-00859-5

Gallacher, Daniel C., Auguste, Peter and Connock, M. (2019) How do pharmaceutical companies model survival of cancer patients? A review of NICE Single Technology Appraisals in 2017. International Journal of Technology Assessment in Health Care, 35 (2). pp. 160-167. doi:10.1017/S0266462319000175

Gallacher, Daniel C., Armoiry, Xavier, Auguste, Peter, Court, Rachel A., Mantopoulos, Theodoros, Patterson, Jacoby, De Santis, Maria , Cresswell, Joanne and Mistry, Hema (2019) Pembrolizumab for previously treated advanced or metastatic urothelial cancer : an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 37 . pp. 19-27. doi:10.1007/s40273-018-0689-3

Connock, Martin, Auguste, Peter, Dussart, Claude, Guyotat, Jacques and Armoiry, Xavier (2019) Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma : an updated evaluation using a partitioned survival model. Journal of Neuro-Oncology . pp. 1-7. doi:10.1007/s11060-019-03197-w

2018

Melendez-Torres, G. J., Armoiry, Xavier, Court, Rachel A., Patterson, Jacoby, Kan, Alan, Auguste, Peter, Madan, Jason, Counsell, Carl, Ciccarelli, Olga and Clarke, Aileen (2018) Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis : systematic review and network meta-analysis of trials including recommended dosages. BMC Neurology, 18 (1). doi:10.1186/s12883-018-1162-9

NICE Project Team and Appraisal Committee Members (Including: Armoiry, Xavier, Auguste, Peter and Clarke, Aileen). (2018) Beta interferons and glatiramer acetate for treating multiple sclerosis. National Institute for Health and Care Excellence.

Armoiry, Xavier, Kanda, Akira, Melendez-Torres, G. J., Court, Rachel A., Sutcliffe, P. (Paul), Auguste, Peter, Madan, Jason, Counsell, C. and Clarke, Aileen (2018) Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome : a systematic review of randomised controlled trials and network meta-analysis. Journal of Neurology, 265 (5). pp. 999-1009. doi:10.1007/s00415-018-8752-8

2017

Mistry, Hema, Auguste, Peter, Lois, Noemi and Waugh, Norman (2017) Diabetic retinopathy and the use of laser photocoagulation : is it cost-effective to treat early? BMJ Open Ophthalmology, 2 (1). e000021. doi:10.1136/bmjophth-2016-000021

Melendez-Torres, G. J., Auguste, Peter, Armoiry, Xavier, Maheswaran, H., Court, Rachel A., Madan, Jason, Kan, A., Lin, S., Counsell, C., Patterson, J., Rodrigus, J., Ciccarelli, O., Fraser, Hannah and Clarke, Aileen (2017) Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation. Health Technology Assessment, 21 (52). doi:10.3310/hta21520

Melendez-Torres, GJ, Auguste, Peter, Armoiry, Xavier, Maheswaran, Hendramoorthy, Court, Rachel A., Madan, Jason, Kan, Alan, Lin, Stephanie, Counsell, Carl, Patterson, Jacoby, Rodrigues, Jeremy, Ciccarelli, Olga, Fraser, Hannah and Clarke, Aileen (2017) Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment, 21 (52). pp. 1-352. doi:10.3310/hta21520

Freeman, Karoline, Taylor-Phillips, Sian, Connock, M., Court, Rachel A., Tsertsvadze, Alexander, Shyangdan, D. (Deepson), Auguste, Peter, Mistry, Hema, Arasaradnam, Ramesh P., Sutcliffe, P. (Paul) and Clarke, Aileen (2017) Test accuracy of drug and antibody assays for predicting response to anti-Tumour Necrosis Factor treatment in Crohn’s disease : a systematic review and meta-analysis. BMJ Open, 7 . e014581.

Auguste, Peter, Tsertsvadze, Alexander, Pink, Joshua, Court, Rachel A., McCarthy, Noel D., Sutcliffe, P. (Paul) and Clarke, Aileen (2017) Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis : systematic review and meta-analysis. BMC Infectious Diseases, 17 (1). doi:10.1186/s12879-017-2301-4

2016

Freeman, Karoline, Connock, M., Auguste, Peter, Taylor-Phillips, Sian, Mistry, Hema, Shyangdan, D. (Deepson), Court, Rachel A., Arasaradnam, Ramesh P., Sutcliffe, P. (Paul) and Clarke, Aileen (2016) Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Health Technology Assessment, 20 (83). pp. 1-288. doi:10.3310/hta20830

Auguste, Peter, Tsertsvadze, Alexander, Court, Rachel A. and Pink, Joshua (2016) A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis, 99 . pp. 81-91. doi:10.1016/j.tube.2016.04.007

Auguste, Peter, Tsertsvadze, Alexander, Pink, Joshua, Court, Rachel A., Seedat, Farah, Gurung, Tara, Freeman, Karoline, Taylor-Phillips, Sian, Walker, Clare, Madan, Jason, Kandala, Ngianga-Bakwin, Clarke, Aileen and Sutcliffe, P. (Paul) (2016) Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis : systematic review and economic evaluation. Health Technology Assessment, 20 (38). pp. 1-678. doi:10.3310/hta20380

2015

Royle, Pamela, Mistry, Hema, Auguste, Peter, Shyangdan, D., Freeman, Karoline, Lois, Noemi and Waugh, Norman (2015) Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy : systematic review and economic evaluation. Health Technology Assessment, 19 (51). pp. 1-248. doi:10.3310/hta19510

2014

Mistry, Hema, Auguste, Peter, Lois, Noemi and Waugh, Norman (2014) Non-proliferative diabetic retinopathy : is it cost-effective to treat early? Value in Health, 17 (7). a609. doi:10.1016/j.jval.2014.08.2130

Meads, C., Davenport, C., Malysiak, S., Kowalska, Marta, Zapalska, A., Guest, P., Martin-Hirsch, P. L., Borowiack, E., Auguste, Peter, Barton, P., Roberts, T. P., Khan, K. and Sundar, Santhanam (2014) Evaluating PET-CT in the detection and management of recurrent cervical cancer : systematic reviews of diagnostic accuracy and subjective elicitation. BJOG: An International Journal of Obstetrics & Gynaecology, 121 (4). pp. 398-407. doi:10.1111/1471-0528.12488

Auguste, Peter, Barton, P., Meads, C., Davenport, C., Malysiak, S., Kowalska, Marta, Zapalska, A., Guest, P., Martin-Hirsch, P. L., Borowiack, E., Khan, K., Sundar, Santhanam and Roberts, T. (2014) Evaluating PET–CT in routine surveillance and follow-up after treatment for cervical cancer : a cost-effectiveness analysis. BJOG : An International Journal of Obstetrics & Gynaecology, 121 (4). pp. 464-476. doi:10.1111/1471-0528.12460

Jackson, Louise J., Auguste, Peter, Lowen, Nicola and Roberts, Tracy E. (2014) Valuing the health states associated with Chlamydia trachomatis infections and their sequelae : a systematic review of economic evaluations and primary studies. Value in Health, Volume 17 (Number 1). pp. 116-130. doi:10.1016/j.jval.2013.10.005

Althaus, Christian L., Turner, Katherine M. E., Mercer, Catherine H., Auguste, Peter, Roberts, Tracy E., Bell, Gill, Herzog, Sereina A., Cassell, Jackie A., Edmunds, W. John , White, Peter J., Ward, Helen and Low, Nicola (2014) Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections : observational study, systematic reviews and mathematical modelling. Health Technology Assessment, 18 (2). doi:10.3310/hta18020

2012

Green, Colin, Auguste, Peter, Lloyd, J. L. and Wyatt, K. M. (2012) Modelling future outcomes to estimate the cost-effectiveness of interventions related to childhood/adolescent overweight/obesity. The Lancet, 380 . s43. doi:10.1016/S0140-6736(13)60399-2

Roberts, T. E., Barton, P. M., Auguste, Peter, Middleton, L. J., Furmston, A. T. and Ewer, A. K. (2012) Pulse oximetry as a screening test for congenital heart defects in newborn infants : a cost-effectiveness analysis. Archives of Disease in Childhood, 97 (3). pp. 221-226. doi:10.1136/archdischild-2011-300564

Ewer, A. K., Furmston, A. T., Middleton, L. J., Deeks, J. J., Daniels, J. P., Pattison, H. M., Powell, R., Roberts, T. E., Barton, P., Auguste, Peter, Bhoyar, A., Thangaratinam, S. (Shakila), Tonks, A. M., Satodia, P., Deshpande, S., Kumararatne, B., Sivakumar, S., Mupanemunda, R. and Khan, K. S. (2012) Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technology Assessment, 16 (2). doi:10.3310/hta16020

2011

Auguste, Peter, Barton, P., Hyde, C. and Roberts, T. E. (2011) An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment, 15 (18). doi:10.3310/hta15180